Document Detail

Influence of multidrug resistance on (18)F-FCH cellular uptake in a glioblastoma model.
MedLine Citation:
PMID:  19300998     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Multidrug resistance, aggressiveness and accelerated choline metabolism are hallmarks of malignancy and have motivated the development of new PET tracers like (18)F-FCH, an analogue of choline. Our aim was to study the relationship of multidrug resistance of cultured glioma cell lines and (18)F-FCH tracer uptake. METHODS: We used an in vitro multidrug-resistant (MDR) glioma model composed of sensitive parental U87MG and derived resistant cells U87MG-CIS and U87MG-DOX. Aggressiveness, choline metabolism and transport were studied, particularly the expression of choline kinase (CK) and high-affinity choline transporter (CHT1). FCH transport studies were assessed in our glioblastoma model. RESULTS: As expected, the resistant cell lines express P-glycoprotein (Pgp), multidrug resistance-associated protein isoform 1 (MRP1) and elevated glutathione (GSH) content and are also more mobile and more invasive than the sensitive U87MG cells. Our results show an overexpression of CK and CHT1 in the resistant cell lines compared to the sensitive cell lines. We found an increased uptake of FCH (in % of uptake per 200,000 cells) in the resistant cells compared to the sensitive ones (U87MG: 0.89 +/- 0.14; U87MG-CIS: 1.27 +/- 0.18; U87MG-DOX: 1.33 +/- 0.13) in line with accelerated choline metabolism and aggressive phenotype. CONCLUSIONS: FCH uptake is not influenced by the two ATP-dependant efflux pumps: Pgp and MRP1. FCH would be an interesting probe for glioma imaging which would not be effluxed from the resistant cells by the classic MDR ABC transporters. Our results clearly show that FCH uptake reflects accelerated choline metabolism and is related to tumour aggressiveness and drug resistance.
Claire Vanpouille; Nathalie Le Jeune; David Kryza; Anthony Clotagatide; Marc Janier; Francis Dubois; Nathalie Perek
Related Documents :
9774148 - Pkc-independent modulation of multidrug resistance in cells with mutant (v185) but not ...
11031728 - Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine.
8097728 - Kinetics of cellular permeability of phenoxazine and its dependence on p-glycoprotein e...
1517798 - Fluorescent dye rhodamine 6g as a molecular probe to study drug resistance of c6 rat gl...
23545568 - Stable and high-rate overcharge protection for rechargeable lithium batteries.
16474598 - Mechanisms of disease: specialized interstitial cells of the urinary tract--an assessme...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-03-20
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  36     ISSN:  1619-7089     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-07-13     Completed Date:  2009-09-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1256-64     Citation Subset:  IM    
Université de Lyon, Université Jean Monnet-Cancer Research Group IFRESIS 143, 42023, Saint-Etienne, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Transport
Cell Line, Tumor
Choline / analogs & derivatives*,  diagnostic use,  metabolism
Choline Kinase / metabolism
Drug Resistance, Multiple*
Drug Resistance, Neoplasm*
Gene Expression Regulation, Neoplastic
Glioblastoma / diagnosis,  genetics,  metabolism*,  pathology
Symporters / metabolism
Reg. No./Substance:
0/SLC5A7 protein, human; 0/Symporters; 0/fluorocholine; 62-49-7/Choline; EC Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus m...
Next Document:  Chronic locked posterior shoulder dislocation with severe head involvement.